Healthcare Stocks PGEN and MLYS Double in Value, Analysts Predict Further Gains

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-07 13:49:01

BTCCSquare news:

Precigen (PGEN) and another healthcare stock (MLYS) have surged over 100% since late July, catching Wall Street's attention. Precigen's 155% rally followed FDA approval for its breakthrough immunotherapy Papzimeos—the first treatment for recurrent respiratory papillomatosis. The drug demonstrated durable efficacy, with 15 of 18 initial responders remaining surgery-free after two years.

Analysts see room for further upside despite the steep climbs. The healthcare sector continues to produce asymmetric opportunities, with targeted therapies commanding premium valuations. Market participants are rewarding innovation as regulatory pathways accelerate for high-impact treatments.

By:

Log in to Reply

New ETFs Track Congressional Stock Trades for Democrats and Republicans

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.